Detail
| LncRNA Name | CASC2 |
| Synonyms | CASC2, C10orf5 |
| Region | GRCh38_10:118046279-118210153 Sequence |
| Ensembl | ENSG00000177640 |
| RefSeq | NR_026939 |
| Circulating | ✘ |
| Drug-resisitant | ✔ |
| Prognostic | ✔ |
| MiRNA | ✔ |
| Variant | ✘ |
| TF | ✘ |
| Methylation | ✘ |
| Cancer Name | glioma |
| ICD-0-3 | M9380/3 |
| Methods | qPCR, RNAi, Western blot, RIP, Luciferase reporter assay, MTT assay etc. |
| Sample | glioma tissues, cell lines (U251, U373, SNB19, U118, and LN229) |
| Expression Pattern | down-regulated |
| Function Description | CASC2 expression was down-regulated in glioma tissues and cell lines. Exogenous CACS2 alone was sufficient to inhibit glioma cells' proliferation and amplified TMZ-induced repression of cell proliferation, while CACS2 knockdown could reverse this process. CASC2 up-regulates PTEN through direct inhibiting miR-181a and plays an important role in glioma sensitivity to TMZ and may serve as a potential target for cancer diagnosis and treatment. |
| Pubmed ID | 28121023 |
| Year | 2017 |
| Title | LncRNA CASC2 Interacts With miR-181a to Modulate Glioma Growth and Resistance to TMZ Through PTEN Pathway. |
| External Links |
| Links for CASC2 | GenBank HGNC lncrnadb Noncode |
| Links for glioma | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.